Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04499573
Other study ID # NCPHOI-2020-07
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 27, 2020
Est. completion date March 13, 2027

Study information

Verified date February 2023
Source Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia


Description:

The main objectives of the study are: - To investigate the incidence of adverse events of grade 3-5 within after CD19/CD22 CAR lymphocyte infusion by day 28, - To evaluate the incidence of complete remission and MRD-negative CR by day 28 - To evaluate the long-term effectiveness of CD19/CD22 CAR-T therapy (cumulative incidence of relapse, event-free survival, overall survival) at 1, 2, and 5 years after infusion. - To evaluate the persistence of CD19/CD22 CAR-T cells and duration of B-cell aplasia (<1% B-cells in the blood) and hypogammaglobulinemia In order to prevent the development of CRS, all patients will receive an infusion of tocilizumab at 8 mg/kg body weight on day 0 before CAR-T cells infusion. Step-down and step-up dosing will be used to adapt the trial to the scenario of excess toxicity and/or suboptimal effect. Reevaluation of dosing will be done for each cohort separately after the enrollment 5th study subject reaches day 28 or earlier if the threshold for excess toxicity or suboptimal effect is achieved. Based on interim analysis in March 2021 after the enrollment 5th study subject reaches day 28 study population will be divided into three cohorts: 1. CD19-positive (both CD19 and CD22 expressed on over 50% of leukemia cells), low and high disease burden. 2. CD19-negative (CD22 expressed on over 50% of leukemia cells) low and high disease burden; 3. Allogeneic HSCT+ allogeneic CAR-T cohort


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date March 13, 2027
Est. primary completion date March 13, 2022
Accepts healthy volunteers No
Gender All
Age group 3 Months to 25 Years
Eligibility Inclusion Criteria: - Ability to give informed consent (for patients > 14 years old). For subjects < 18 years old their legal guardian must give informed consent - CD19 or CD22 expression must be detected on greater than 50% of leukemic cells by flow cytometry - Presence of a measurable mass of tumor cells in the bone marrow or extramedullary sites at the time of patient's inclusion in the study - Patients with relapsed or refractory CD19 and CD22-expressing B-cell ALL: - Induction failure - MRD = 0,1% after 2nd chemotherapy course for high-risk group patients. - First bone marrow or combined relapse of acute lymphoblastic leukemia, no CR or MRD = 0,1% after 1-course 2nd line therapy - Second and further relapse of ALL - Relapse or MRD = 0,1% of ALL after hematopoietic stem cell transplant (> 60 days post alloHSCT)o There must be no available alternative approved curative therapies - Patient Clinical Performance Status: Karnofsky >50% or Lansky >50% - Patient Life Expectancy > 4 weeks - Patients recovered from acute toxic effects of prior chemotherapy, immune- or radiotherapy - Patient absolute blood naïve (CD45RA+) T-lymphocyte count = 50/mm3 - Patient cardiac function left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO. - Patients who agree to long-term follow up for up to 5 years (if received CD19/CD22 CAR-T cell infusion) - March 2021 amendment: Healthy HLA-matched related or haploidentical donor (only for HSCT cohort) Exclusion Criteria: - <50% expression of both CD19 and CD22 on the leukemic population - Active (detectable viremia) hepatitis B, C or HIV infection - Oxygen saturation = 90% - Bilirubin >3x upper norma limit - Creatinine >3x upper norma limit - Active acute GVHD overall grade =2 (Seattle criteria) - Moderate/severe chronic GVHD (NIH consensus) requiring systemic steroids - Clinical signs of grade > 3 CNS disorders (seizure disorder, paresis, aphasia, cerebrovascular, ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder) - Pregnant or lactating women. - Active (unresolved) severe infection

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CD19/CD22 CAR-T
The treatment plan will be based on stratification by the initial leukemia burden. Patients with "low disease burden" will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days. Patients will "high disease burden" will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days. Based on interim analysis the following dosing approach will be implemented starting April 2021: Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg

Locations

Country Name City State
Russian Federation Federal Research Institute of Pediatric Hematology, Oncology and Immunology Moscow

Sponsors (1)

Lead Sponsor Collaborator
Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of grade 3-5 SAE Safety:
Toxicity evaluation following CD19/CD22 CAR T-cell infusion:
- incidence of grade 3-5 SAE (according CTCAE v.5.0)
1 month
Primary incidence of grade 3-5 Severe Cytokine Release Syndrome Safety:
Toxicity evaluation following CD19/CD22 CAR T-cell infusion:
- incidence of grade 3-5 Severe Cytokine Release Syndrome (according ASTCT consensus)
1 month
Primary incidence of grade 3-5 ICANS Safety:
Toxicity evaluation following CD19/CD22 CAR T-cell infusion:
- incidence of grade 3-5 ICANS (according to ASTCT consensus)
1 month
Primary Rate of complete remission Efficacy:
- Rate of complete remission among all enrolled patients (Intent-to-Treat population)
1 month
Primary Rate of MRD-negative remission Efficacy:
- Rate of MRD-negative remission among all patients (Intent-to-treat population)
1 month
Primary March 2021 amendment: incidence of graft failure before day 100 (only for HSCT cohort) Safety: 100 days
Primary March 2021 amendment: incidence of aGVHD grade 2-4 (only for HSCT cohort) Safety: 100 days
Secondary Duration of MRD-negative remission Efficacy: 2 years
Secondary Persistence/frequency of CD19/CD22 lymphocytes in peripheral blood (flow cytometry) Efficacy: 2 years
Secondary Duration of B-cell aplasia and hypogammaglobulinemia Efficacy: 2 years
Secondary Overall survival Efficacy: 5 years
Secondary Safety and adverse effects long-term Safety: 5 years
Secondary March 2021 amendment: Incidence of chronic GVHD (only for HSCT cohort) Safety: 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04088890 - Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Phase 1
Recruiting NCT04546893 - Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia N/A
Recruiting NCT04546906 - Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia N/A
Active, not recruiting NCT01209286 - Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Phase 2
Withdrawn NCT05571540 - Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL Phase 1/Phase 2
Completed NCT01290120 - Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma Phase 2
Recruiting NCT04781634 - a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL Phase 1/Phase 2
Recruiting NCT03448393 - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Phase 1
Recruiting NCT05350852 - Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL Phase 1
Recruiting NCT05350787 - Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL Phase 1
Recruiting NCT05621291 - A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu... N/A
Active, not recruiting NCT04318678 - CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) Phase 1
Recruiting NCT04512716 - Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma Early Phase 1
Active, not recruiting NCT03751709 - Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL Phase 1
Recruiting NCT05639179 - Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL Phase 1/Phase 2
Recruiting NCT04792593 - Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia N/A
Recruiting NCT05442515 - CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Phase 1/Phase 2
Active, not recruiting NCT02328014 - Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies Phase 1/Phase 2
Active, not recruiting NCT02315612 - Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies Phase 1